Tags

Type your tag names separated by a space and hit enter

Atrial fibrillation in Brugada syndrome: Current perspectives.

Abstract

The incidence of atrial fibrillation (AF) in Brugada syndrome (BrS) has been reported at between 9% and 53% by different series, but the true prevalence is unknown. However, AF may be the presenting feature in some patients. The underlying mechanisms for AF may be a combination of multiple factors, genetic or acquired, that may impact upon autonomic function, atrial structure, and conduction velocities or other unknown factors. The presence of AF has been associated with a more malignant course, with a greater incidence of syncope and ventricular arrhythmias, thus acting as marker of more advanced disease. Regarding the management of patients with AF, antiarrhythmic drugs effective in preventing malignant arrhythmias in BrS such as quinidine or invasive treatment with pulmonary vein isolation (PVI) may be useful in AF treatment. In this review, we aim to present the current perspectives regarding the genetics, pathophysiology, management, and prognosis of AF in patients with BrS.

Authors+Show Affiliations

Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Cardiology and Electrophysiology Unit, Azienda USL Toscana, Florence, Italy.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France. Department of Electrophysiology-Cardiology, Royal Papworth Hospital, Cambridge, UK.Laboratory of Electrophysiology, Second Department of Cardiology, General Hospital of Athens "Evangelismos", Athens, Greece.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Laboratory of Electrophysiology, Second Department of Cardiology, General Hospital of Athens "Evangelismos", Athens, Greece.Laboratory of Electrophysiology, Second Department of Cardiology, General Hospital of Athens "Evangelismos", Athens, Greece.Laboratory of Electrophysiology, Second Department of Cardiology, General Hospital of Athens "Evangelismos", Athens, Greece.Department of Electrophysiology-Cardiology, Klinikum Vest, Recklinghausen, Germany. Department of Cardiology, Akademisches Lehrkrankenhaus, Ruhr-Universität Bochum, Bochum, Germany.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.Hôpital Cardiologique du Haut Lévèque, CHU de Bordeaux and IHU-LIRYC, Pessac, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31961030

Citation

Vlachos, Konstantinos, et al. "Atrial Fibrillation in Brugada Syndrome: Current Perspectives." Journal of Cardiovascular Electrophysiology, 2020.
Vlachos K, Mascia G, Martin CA, et al. Atrial fibrillation in Brugada syndrome: Current perspectives. J Cardiovasc Electrophysiol. 2020.
Vlachos, K., Mascia, G., Martin, C. A., Bazoukis, G., Frontera, A., Cheniti, G., ... Sacher, F. (2020). Atrial fibrillation in Brugada syndrome: Current perspectives. Journal of Cardiovascular Electrophysiology, doi:10.1111/jce.14361.
Vlachos K, et al. Atrial Fibrillation in Brugada Syndrome: Current Perspectives. J Cardiovasc Electrophysiol. 2020 Jan 21; PubMed PMID: 31961030.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atrial fibrillation in Brugada syndrome: Current perspectives. AU - Vlachos,Konstantinos, AU - Mascia,Giuseppe, AU - Martin,Claire A, AU - Bazoukis,George, AU - Frontera,Antonio, AU - Cheniti,Ghassen, AU - Letsas,Konstantinos P, AU - Efremidis,Micheal, AU - Georgopoulos,Stamatis, AU - Gkalapis,Charis, AU - Duchateau,Josselin, AU - Parmbrun,Thomas, AU - Derval,Nicholas, AU - Hocini,Mélèze, AU - Haissaguerre,Michel, AU - Jais,Pierre, AU - Sacher,Frédéric, Y1 - 2020/01/21/ PY - 2019/11/06/received PY - 2020/01/10/revised PY - 2020/01/15/accepted PY - 2020/1/22/pubmed PY - 2020/1/22/medline PY - 2020/1/22/entrez KW - Brugada syndrome KW - arrhythmia mechanism KW - atrial fibrillation KW - genetics JF - Journal of cardiovascular electrophysiology JO - J. Cardiovasc. Electrophysiol. N2 - The incidence of atrial fibrillation (AF) in Brugada syndrome (BrS) has been reported at between 9% and 53% by different series, but the true prevalence is unknown. However, AF may be the presenting feature in some patients. The underlying mechanisms for AF may be a combination of multiple factors, genetic or acquired, that may impact upon autonomic function, atrial structure, and conduction velocities or other unknown factors. The presence of AF has been associated with a more malignant course, with a greater incidence of syncope and ventricular arrhythmias, thus acting as marker of more advanced disease. Regarding the management of patients with AF, antiarrhythmic drugs effective in preventing malignant arrhythmias in BrS such as quinidine or invasive treatment with pulmonary vein isolation (PVI) may be useful in AF treatment. In this review, we aim to present the current perspectives regarding the genetics, pathophysiology, management, and prognosis of AF in patients with BrS. SN - 1540-8167 UR - https://www.unboundmedicine.com/medline/citation/31961030/Atrial_fibrillation_in_Brugada_syndrome:_Current_perspectives L2 - https://doi.org/10.1111/jce.14361 DB - PRIME DP - Unbound Medicine ER -